SynOx Therapeutics 🇮🇪
Series B · $75M
Dublin/Oxford late-stage biopharma developing emactuzumab for tenosynovial giant cell tumour
About SynOx Therapeutics
SynOx Therapeutics is developing a next-generation monoclonal antibody that targets CSF-1R, specifically emactuzumab, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven diseases. This therapeutic approach leverages the antibody's well-tolerated safety profile and promising efficacy observed in clinical settings.
SynOx Therapeutics is a Ireland-based company founded in 2020, now around 33 people. It has raised $75M in disclosed funding. FundFinder classes it as Health & Bio.
Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.
Want the latest on SynOx Therapeutics? Our research agent pulls the current
description, latest round and full investor base from public sources (about a minute).
Series B · $75M · Apr 2024
InvestorsHHealthCap
- HealthCap — HealthCap is a life sciences venture investor and company creator based in Stockholm and founded in 1996.